Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 12/20 | 0.86 |
| ▸ | KDR | P35968 | 10/20 | 0.86 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.86 |
| ▸ | TLK2 | Q86UE8 | 5/20 | 0.86 |
| ▸ | PRKAA1 | Q13131 | 8/20 | 0.73 |
| ▸ | PRKAA2 | P54646 | 7/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.70 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.70 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.70 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.70 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.70 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.70 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.70 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.70 |
| ▸ | PLK4 | O00444 | 3/20 | 0.69 |
| ▸ | DCLK1 | O15075 | 3/20 | 0.69 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22649616 | 0.96 | PDGFRB (0.79) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| Toceranib SCHEMBL2116670 | 0.93 | PDGFRB (1.00) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| Toceranib SCHEMBL29354429 | 0.93 | PDGFRB (1.00) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL31672513 | 0.93 | PDGFRB (0.90) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| Toceranib SCHEMBL1673439 | 0.93 | PDGFRB (1.00) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL2115759 | 0.93 | PDGFRB (0.90) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL22649592 | 0.91 | PDGFRB (0.87) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL2114506 | 0.91 | PDGFRB (0.81) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| SCHEMBL5830182 | 0.90 | PDGFRB (1.00) | PDGFRBKDRFGFR1TLK2PRKAA1 | |
| Toceranib SCHEMBL29397832 | 0.90 | PDGFRB (0.95) | PDGFRBKDRFGFR1TLK2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-01-26 | — | — | US | disclosed |
| WO-2020227325-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022524-A1 | HETEROBIFUNCTIONAL COMPOUNDS AS DEGRADERS OF HPK1 | HIPK1, MCL1, HYPK | PDGFRB 832/4885KDR 1242/4885FGFR1 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.